125 related articles for article (PubMed ID: 35703792)
21. The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines.
Watanabe Y; Endo S; Nishihara K; Ueda K; Mine M; Tamiya S; Nakano T; Tanaka M
Surg Today; 2018 Nov; 48(11):1011-1019. PubMed ID: 29961172
[TBL] [Abstract][Full Text] [Related]
22. Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management.
Crippa S; Pezzilli R; Bissolati M; Capurso G; Romano L; Brunori MP; Calculli L; Tamburrino D; Piccioli A; Ruffo G; Fave GD; Falconi M
Am J Gastroenterol; 2017 Jul; 112(7):1153-1161. PubMed ID: 28244498
[TBL] [Abstract][Full Text] [Related]
23. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis.
Chhoda A; Singh S; Sheth AH; Grimshaw AA; Gunderson CG; Sharma P; Kunstman JW; Sharma A; Ahuja N; Gonda TA; Farrell JJ
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1430-1446. PubMed ID: 35568304
[TBL] [Abstract][Full Text] [Related]
24. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma.
Morales-Oyarvide V; Mino-Kenudson M; Ferrone CR; Sahani DV; Pergolini I; Negreros-Osuna AA; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Pancreatology; 2017; 17(6):920-926. PubMed ID: 28890154
[TBL] [Abstract][Full Text] [Related]
25. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
26. Anatomical pancreatic variants in intraductal papillary mucinous neoplasm patients: a cross-sectional study.
Johansson K; Mustonen H; Seppänen H; Lehtimäki TE
BMC Gastroenterol; 2022 Aug; 22(1):394. PubMed ID: 35989322
[TBL] [Abstract][Full Text] [Related]
27. Radiological and Pathological Assessment of the 2017 Revised International Association of Pancreatology Consensus Guidelines for Intraductal Papillary Mucinous Neoplasm, With an Emphasis on the Gastric Pyloric Gland Type.
Nakahodo J; Fukumura Y; Saito T; Mitomi H; Saiura A; Fujisawa T; Ishii S; Isayama H; Kurahayashi I; Yao T
Pancreas; 2020 Feb; 49(2):216-223. PubMed ID: 32011532
[TBL] [Abstract][Full Text] [Related]
28. The role of pancreatic juice cytology in the diagnosis of pancreatic intraductal papillary mucinous neoplasm.
Tag-Adeen M; Ozawa E; Ogihara K; Iwatsu S; Akazawa Y; Ohnita K; Adachi T; Sumida Y; Nakao K
Rev Esp Enferm Dig; 2018 Dec; 110(12):775-781. PubMed ID: 30168338
[TBL] [Abstract][Full Text] [Related]
29. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
30. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
31. Risk Factors for the Development of High-risk Stigmata in Branch-duct Intraductal Papillary Mucinous Neoplasms.
Yamazaki T; Tomoda T; Kato H; Miyamoto K; Matsumi A; Ueta E; Fujii Y; Saragai Y; Uchida D; Matsumoto K; Horiguchi S; Tsutsumi K; Okada H
Intern Med; 2021 Oct; 60(20):3205-3211. PubMed ID: 33967138
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of low-risk branch-duct IPMNs of the pancreas: is main pancreatic duct dilatation the most worrisome feature?
Petrone MC; Magnoni P; Pergolini I; Capurso G; Traini M; Doglioni C; Mariani A; Crippa S; Arcidiacono PG
Clin Transl Gastroenterol; 2018 Jun; 9(6):158. PubMed ID: 29895904
[TBL] [Abstract][Full Text] [Related]
33. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
34. [Branch duct intraductal papillary mucinous neoplasm - contra resection].
Brunner M; Weber GF; Kersting S; Grützmann R
Chirurg; 2017 Nov; 88(11):918-926. PubMed ID: 28871376
[TBL] [Abstract][Full Text] [Related]
35. Abnormal serum pancreatic enzymes, but not pancreatitis, are associated with an increased risk of malignancy in patients with intraductal papillary mucinous neoplasms.
Roch AM; Parikh JA; Al-Haddad MA; DeWitt JM; Ceppa EP; House MG; Nakeeb A; Schmidt CM
Surgery; 2014 Oct; 156(4):923-9. PubMed ID: 25239347
[TBL] [Abstract][Full Text] [Related]
36. Treatment of branch-duct intraductal papillary mucinous neoplasms of the pancreas: state of the art.
Crippa S; Piccioli A; Salandini MC; Cova C; Aleotti F; Falconi M
Updates Surg; 2016 Sep; 68(3):265-271. PubMed ID: 27502606
[TBL] [Abstract][Full Text] [Related]
37. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
38. Importance of main pancreatic duct dilatation in IPMN undergoing surveillance.
Marchegiani G; Andrianello S; Morbin G; Secchettin E; D'Onofrio M; De Robertis R; Malleo G; Bassi C; Salvia R
Br J Surg; 2018 Dec; 105(13):1825-1834. PubMed ID: 30106195
[TBL] [Abstract][Full Text] [Related]
39. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis.
Crippa S; Bassi C; Salvia R; Malleo G; Marchegiani G; Rebours V; Levy P; Partelli S; Suleiman SL; Banks PA; Ahmed N; Chari ST; Fernández-Del Castillo C; Falconi M
Gut; 2017 Mar; 66(3):495-506. PubMed ID: 26743012
[TBL] [Abstract][Full Text] [Related]
40. "High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas.
Aso T; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Ideno N; Osoegawa T; Takahata S; Shindo K; Ushijima Y; Aishima S; Oda Y; Ito T; Mizumoto K; Tanaka M
Pancreas; 2014 Nov; 43(8):1239-43. PubMed ID: 25036910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
